Parkinson’s Disease / 2018 / Article / Tab 1

Clinical Study

Accuracy of Markerless 3D Motion Capture Evaluation to Differentiate between On/Off Status in Parkinson’s Disease after Deep Brain Stimulation

Table 1

Parkinson patients at the time of evaluation.

PatientAgeTime since diagnosisTime since DBS implantationPD medicationUPDRS score OffUPDRS score On

1675 years10 monthsL-dopa, rotigotine4722
26512 years5 monthsL-dopa, rotigotine, amantadine5327
3445 years6 monthsL-dopa, biperidone3929
47610 years12 monthsL-dopa, rotigotine, amantadine4237
5595 years11 monthsL-dopa, rotigotine5741
66310 years46 monthsL-dopa, rotigotine, rasagiline4025

PD medication doses: L-dopa ranged from 400 to 1000 mg per day, rotigotine 4–8 mg per day, amantadine ranged from 100 to 300 mg per day, and rasagiline 1 mg per day.

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.